Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Castle Biosciences (CSTL) Stock Price & Analysis
283 Followers
CSTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.58 - $48.40
Previous Close$28.3
Volume126.45K
Average Volume (3M)175.77K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$265.98M
Total Debt (Recent Filing)$13.44M
Price to Earnings (P/E)-13.8
Beta1.59
Next EarningsMar 14, 2023
EPS Estimate-$0.84
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$48.00
EPS (TTM)-2.06
Shares Outstanding26,351,576
R-Squared0.10
Standard Deviation0.18
10 Day Avg. Volume122,310
30 Day Avg. Volume175,770
Price to Book (P/B)2.54
Price to Sales (P/S)7.35
Price to Cash Flow (P/CF)230.60
P/FCF Ratio-10.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside69.61% Upside
Rating ConsensusModerate Buy
Alpha0.02
Number of Analyst Covering2
Castle Biosciences News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $15.58 and its highest was $48.40 in the past 12 months.
What is Castle Biosciences’s market cap?
Currently, no data Available
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 14, 2023 which is in 38 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Nov 02, 2022. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.111.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -$0.84.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 26,351,576 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -2.019%.
Which hedge fund is a major shareholder of Castle Biosciences?
Among the largest hedge funds holding Castle Biosciences’s share is Graham Capital Management, L.P.. It holds Castle Biosciences’s shares valued at 1M.
---
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.00
$48.00
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 27.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $88.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.13%
12-Months-Change
Fundamentals
Return on Equity
-12.87%
Trailing 12-Months
Asset Growth
5.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
---